Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Ovarian Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × vofatamab × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡